Phreesia (NYSE:PHR) Stock Rating Reaffirmed by Truist Financial

Truist Financial reaffirmed their buy rating on shares of Phreesia (NYSE:PHR) in a research note published on Monday morning, Benzinga reports. The firm currently has a $29.00 price objective on the stock.

Several other brokerages also recently commented on PHR. Robert W. Baird increased their price objective on shares of Phreesia from $30.00 to $31.00 and gave the company an outperform rating in a research report on Monday, March 18th. DA Davidson reissued a neutral rating and set a $32.00 price objective on shares of Phreesia in a research report on Friday, March 15th. Royal Bank of Canada reissued a sector perform rating and set a $23.00 price objective on shares of Phreesia in a research report on Thursday, March 21st. Needham & Company LLC reissued a buy rating and set a $29.00 price objective on shares of Phreesia in a research report on Friday, May 31st. Finally, Raymond James reissued an outperform rating and set a $30.00 price objective (up from $25.00) on shares of Phreesia in a research report on Friday, March 15th. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the stock. According to MarketBeat.com, Phreesia currently has an average rating of Moderate Buy and an average price target of $30.92.

Phreesia Stock Up 0.0 %

Shares of NYSE PHR opened at $20.51 on Monday. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.03. Phreesia has a 12 month low of $12.05 and a 12 month high of $34.98. The firm has a market capitalization of $1.18 billion, a PE ratio of -9.45 and a beta of 0.93. The firm has a fifty day simple moving average of $21.20 and a two-hundred day simple moving average of $23.18.

Phreesia (NYSE:PHR) last released its earnings results on Thursday, May 30th. The company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.51) by $0.16. The firm had revenue of $101.20 million for the quarter, compared to the consensus estimate of $100.94 million. Phreesia had a negative net margin of 31.87% and a negative return on equity of 46.89%. The company’s revenue was up 20.8% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.70) EPS. Equities analysts expect that Phreesia will post -1.18 earnings per share for the current year.

Insider Activity at Phreesia

In other Phreesia news, insider Janet Gunzburg sold 2,768 shares of Phreesia stock in a transaction on Wednesday, April 10th. The shares were sold at an average price of $23.10, for a total transaction of $63,940.80. Following the completion of the transaction, the insider now directly owns 36,132 shares of the company’s stock, valued at $834,649.20. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. In other Phreesia news, CEO Chaim Indig sold 12,043 shares of Phreesia stock in a transaction on Monday, April 8th. The shares were sold at an average price of $22.62, for a total transaction of $272,412.66. Following the completion of the transaction, the chief executive officer now directly owns 1,225,397 shares of the company’s stock, valued at $27,718,480.14. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Janet Gunzburg sold 2,768 shares of Phreesia stock in a transaction on Wednesday, April 10th. The stock was sold at an average price of $23.10, for a total value of $63,940.80. Following the sale, the insider now owns 36,132 shares of the company’s stock, valued at $834,649.20. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 50,359 shares of company stock valued at $1,141,645. 5.80% of the stock is owned by corporate insiders.

Institutional Trading of Phreesia

Several institutional investors and hedge funds have recently made changes to their positions in the business. Boston Partners bought a new stake in shares of Phreesia during the first quarter worth $669,000. Silvercrest Asset Management Group LLC lifted its position in shares of Phreesia by 4.5% during the first quarter. Silvercrest Asset Management Group LLC now owns 447,638 shares of the company’s stock worth $10,712,000 after purchasing an additional 19,454 shares during the last quarter. Bellevue Group AG lifted its position in shares of Phreesia by 5.2% during the first quarter. Bellevue Group AG now owns 443,341 shares of the company’s stock worth $10,609,000 after purchasing an additional 21,768 shares during the last quarter. Quadrature Capital Ltd bought a new stake in shares of Phreesia in the first quarter valued at about $202,000. Finally, Capital International Investors raised its holdings in shares of Phreesia by 221.1% in the first quarter. Capital International Investors now owns 2,593,063 shares of the company’s stock valued at $62,052,000 after acquiring an additional 1,785,463 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.